COPD's early origins in low-and-middle income countries: what are the implications of a false start?

Brakema, EA

http://hdl.handle.net/10026.1/14415

10.1038/s41533-019-0117-y
npj Primary Care Respiratory Medicine
Nature Research (part of Springer Nature)

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
COPD’s early origins in low-and-middle income countries: what are the implications of a false start?

E. A. Brakema, F. A. van Gemert, R. M. J. J. van der Kleij, S. Salvi, M. Puhan, N. H. Chavannes and the FRESH AIR collaborators

npj Primary Care Respiratory Medicine (2019)29:6; https://doi.org/10.1038/s41533-019-0117-y

The Global Initiative for chronic Obstructive Lung disease (GOLD) guideline of 2018 describes COPD as ‘the result of a complex interplay of long-term cumulative exposure to noxious gases and particles, combined with a variety of host factors including genetics, airway hyper-responsiveness and poor lung growth during childhood’.1 Tobacco smoking is traditionally viewed as the main contributing factor to the development of COPD. However, COPD also occurs among non-smokers, especially in low-income and middle-income countries (LMICs).2,3 Notably, more than 90% of COPD-related deaths occur in LMICs.4 For these countries, other risk factors, such as ambient, occupational and household air pollution play a significant role in the development of COPD.2,5–7 Does COPD in these settings have a different pathophysiological trajectory compared to COPD in high-income countries, and if so: what does this imply?

In normal lung development, airway branching is completed by the 17th week of gestation, after which airways increase in volume until young adulthood. Alveoli are present at birth and develop further during childhood. Lung volume and airflow continue to increase as the thorax grows, influenced by age, sex, and ethnicity, reaching a peak at young adulthood. Lung function then remains constant for about 10 years (the plateau phase), after which it gradually declines.8 In the ‘classic’ COPD patient, the decline in lung function is more rapid than in healthy individuals. However, in a considerable proportion of COPD patients, lung function does not decline rapidly, but reaches a lower plateau phase in early adulthood instead. For these patients, a completely different pathophysiological trajectory seems to lead to the diagnosis of COPD: the decline in lung function follows a normal pattern, yet they seem to have a ‘false start’ by attaining a lower maximum lung function.8–11 Several factors can contribute to a lower maximum lung function. There is increasing evidence that different environmental factors (such as tobacco smoke, household air pollution caused by burning solid fuels or kerosene lamps), maternal factors (malnutrition, asthma, diabetes), and gene–environment interactions can impact lung growth. Additionally, childhood factors (low birth weight, prematurity) and other diseases during childhood (lower respiratory tract infections, asthma, tuberculosis, HIV) may all contribute to a decline in lung function.1,3,5,6,9,11–14 (Mal) nutrition additionally plays a vital role in lung development.15 Unfortunately, many of these factors commonly interrelate and co-occur in LMICs. A low socioeconomic status can furthermore deteriorate the situation, as this is not only independently associated with a lower lung function, but also with other health risks (poor access to healthcare, poor nutrition, low birth weight, exposure to indoor and outdoor pollution, poor living conditions and water supply/sanitation).16–18 Overall, populations in LMICs are particularly vulnerable to such risk factors for a lower maximum lung function.16,18

Our knowledge about reduced maximum attained lung functions caused by ‘early life disadvantage factors’ in LMICs seems humble compared to the knowledge generated by extensive research on tobacco-related COPD, often conducted in high-income countries.5,9,11,13,19 The question is whether these early life, disadvantageous factors cause different COPD phenotypes with their own pathophysiology, diagnostic approach, rate of lung function decline, response to treatment, and potential reversibility.3,9,13,19 The paucity of data indicates differences may exist, and that those with a lower forced expiratory volume in one second in early adulthood are also exposed to an increased prevalence and earlier incidence of other non-communicable diseases and premature death.5,12,20,21 Additionally, COPD related to biomass fuel smoke was demonstrated to be commonly present among young, non-smoking women,6 whereas ‘classic’ COPD patients are elderly, smoking men. Such difference could be attributed to differences in risk exposure between men and women, yet potential differences in sensitivity to COPD between men and women per phenotype could play an additional role. Furthermore, as rates of lung function decline vary according to birth, continue throughout childhood and then be combined with the ‘regular’ preventive measures targeting an accelerated decline. As early life disadvantage factors are diverse, prevention addressing these factors should be equally diverse. We argue that raising awareness on COPD is therefore crucial. COPD, the third cause of death worldwide, is often completely unknown to local community members, including their healthcare professionals and policy makers.22 Local curricula for healthcare professionals (doctors,
Increased awareness on the early development of COPD and on the existence of COPD in general could enhance early diagnosis and timely action. Increased awareness is particularly important considering the widescale underdiagnosis of COPD. This raises the question how to best diagnose the disease (affordably, easy to learn), and how to do so at an early stage.6,23 Although affordable medications to treat COPD in LMICs are rare, non-pharmacological approaches, such as pulmonary rehabilitation and patient education can impact COPD symptoms and disease progression. Particularly in LMICs, these approaches seem cost-effective (if not, cost-saving).24

The second implication is related to research. As outlined earlier, more research into a lower maximum lung function and its clinical implications is needed. Furthermore, a false start implies a different perspective on how to study the effect of interventions targeting household air pollution on lung function. For decades, clean cook stove programmes fail to demonstrate consistent positive effects on lung function.16 This often is attributed to flawed implementation of such interventions, or to cross-contamination of air pollution within the community. However, even after successful adoption of clean cook stoves, the lungs in this generation could remain irreversibly damaged. Instead, should we not measure effects on lung function among children and adolescents, or even among the next (unborn) generation?

To conclude, COPD development generally starts early in life due to a complex interplay of disadvantageous factors. Many of these factors particularly occur in LMICs. To address the silent growing epidemic of COPD in LMICs, lung health should be optimised even before birth and in early childhood. Prevention is key, and focus should be on creating large-scale awareness—beyond the healthcare system only, involving all stakeholders. More research is needed to explore the implications of early life disadvantage factors for COPD in LMICs. This should lead to an evidence-based approach for those with a false start—those (at risk of) having a lower maximum lung function.

FRESH AIR COLLABORATORS

Pham Le An¹, Marilena Anastasaki², Meerim Akmatalieva³, Azamat Akylbekov⁴, Andy Barton⁵, Antonios Bertsias⁶, Pham Duong Uyen Binh⁷, Job F. M. van Boven⁸, Dennis Burges⁹, Lucy Cartwright⁹, Vasiliki E. Chatzea¹⁰, Liza Cragg¹¹, Tran Ngoc Dang¹², Ilyas Daoutov¹³, Berik Emilov¹⁴, Irene Ferarrio¹⁵, Ben Hedrick¹⁶, Le Huynh Thi Cam Hong¹⁷, Nick Hopkins¹⁸, Elvira Isavea¹⁹, Rupert Jones²⁰, Corina de Jong²¹, Samne van Kampen²², Wincelaus Katagira²³, Bruce Kringel²⁴, Jesper Kjergaard²⁵,²⁶, Janwiliem Kocks²⁷, Le Thi Tuyet Lan²⁸, Tran Thanh Duy Linh²⁹, Christos Lioni³⁰, Kim Xuan Loan³¹, Maamad Madernilov³², Andy McEwen³³, Patrick Musinguzi³⁴, Rebecca Nantanda³⁵, Grace Ndezive³⁶, Sophia Papadakisa³⁷, Hilary Pinnock³⁸, Jillian Pooler³⁹, Charlotte Poot⁴⁰, Ioanna Tsiligianni⁴¹, Tran Diep Tuan⁴², James Tumwine⁴³, Le Thanh Van⁴⁴, Nguyen Nhu Vinh⁴⁵, Simon Walusimbi⁴⁶, Louise Warren⁴⁷, Sian Williams⁴⁸, Andy McEwen⁴⁹, Patrick Musinguzi⁵⁰, Rebecca Nantanda⁵¹, Grace Ndezive⁵², Sophia Papadakisa⁵³, Hilary Pinnock⁵⁴, Jillian Pooler⁵⁵, Charlotte Poot⁵⁶, Ioanna Tsiligianni⁵⁷, Tran Diep Tuan⁵⁸, James Tumwine⁵⁹, Le Thanh Van⁶⁰, Nguyen Nhu Vinh⁶¹, Simon Walusimbi⁶², Louise Warren⁶³, Sian Williams⁶⁴

¹University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam; ²Clinic of Social and Family Medicine, School of Medicine, University of Crete, Heraklion, Greece; ³Ministry of Health of the Kyrgyz Republic, National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan; ⁴Faculty of Medicine and Dentistry, University of Plymouth, Plymouth, UK; ⁵University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; ⁶Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA; ⁷International Primary Care Respiratory Group, London, UK; ⁸European Lung Foundation, Sheffield, UK; ⁹Imperial College London, London, UK; ¹⁰Makeere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda; ¹¹The Research Unit for General Practice and Section of General Practice, Department of Public Health, Copenhagen University, Copenhagen, Denmark; ¹²Global Health Unit, The Department of Paediatics and Adolescent Health, Juliane Marie Center, Copenhagen University Hospital “Rigshospitalet”, Copenhagen, Denmark; ¹³National Centre for Smoking Cessation and Training, Dorchester, UK; ¹⁴University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK; ¹⁵Coventry University, Coventry, UK and ¹⁶University of Minho, School of Medicine, Braga, Portugal

AUTHOR CONTRIBUTIONS

E.A.B. wrote the first version and subsequent versions of this manuscript in close collaboration with F.v.G. R.v.d.K., M.P., S.S., and N.C. gave input throughout the entire process.

ADDITIONAL INFORMATION

Competing interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary (2018 report) (2018).
2. Gordon, S. B. et al. Respiratory risks from household air pollution in low and middle income countries. Lancet Respir. Med. 2, 823–860 (2014).
3. Salvi, S. S. & Barnes, P. J. Chronic obstructive pulmonary disease in non-smokers. Lancet 374, 733–743 (2009).
4. World Health Organization. Chronic obstructive pulmonary disease (COPD). Fact sheet December 2017. http://www.who.int/en/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) (2017).
5. Sood, A. et al. ERS/ATS workshop report on respiratory health effects of household air pollution. Eur Respir J 51, pii: 1700698; https://doi.org/10.1183/13993003.00698-2017 (2018).
6. van Gemert, F. et al. Prevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional observational study. Lancet Glob. Health 3, e44–e51 (2015).
7. Brakema, E. A. et al. High COPD prevalence at high altitude: does household air pollution play a role? Eur. Respir. J. 53, 1801193, https://doi.org/10.1183/13993003.01193-2018 (2019).
8. Rennard, S. I. & Drummond, M. B. Early chronic obstructive pulmonary disease: definition, assessment, and prevention. Lancet 385, 1778–1788 (2015).
9. Postma, D. S., Bush, A. & van den Berge, M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet 385, 899–909 (2015).
10. Lange, P. et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N. Engl. J. Med. 373, 111–122 (2015).
11. Martinez, F. D. Early-life origins of chronic obstructive pulmonary disease. N. Engl. J. Med. 375, 871–878 (2016).
12. Celli, B. R. & Agusti, A. COPD: time to improve its taxonomy? ERJ Open Res. 4, 00132–2017, https://doi.org/10.1183/23120541.00132-2017 (2018).
13. Bush, A. Lung development and aging. Ann. Am. Thorac. Soc. 13, 5438–5446 (2016).
14. Baraldi, E. & Filippone, M. Chronic lung disease after premature birth. N. Engl. J. Med. 357, 1946–1955 (2007).
15. Ariglian, M., Spinelli, A. M., Liguoro, I. & Cogo, P. Nutrition and lung growth. Nutrients 10, https://doi.org/10.3390/nu10070919 (2018).
16. Pleasants, R. A., Riley, I. L. & Mannino, D. M. Defining and targeting health disparities in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 11, 2475–2496 (2016).
17. Torres-Duque, C. A. Poverty cannot be inhaled and it is not a genetic condition. How can it be associated with chronic airflow obstruction? Eur. Respir. J. 49, https://doi.org/10.1183/13993003.00823-2017 (2017).
18. Grisgby, M. et al. Socioeconomic status and COPD among low- and middle-income countries. Int. J. Chron. Obstruct. Pulmon. Dis. 11, 2497–2507 (2016).
19. Agusti, A. & Celli, B. Natural history of COPD: gaps and opportunities. ERJ Open Res. 3, https://doi.org/10.1183/23120541.00117-2017 (2017).
20. Assaad, N. A., Balmes, J., Mehta, S., Cheema, U. & Sood, A. Chronic obstructive pulmonary disease secondary to household air pollution. Semin. Respir. Crit. Care Med. 36, 408–421 (2015).
21. Agustí, A., Noell, G., Brugada, J. & Faner, R. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. *Lancet Respir. Med.* **5**, 935–945 (2017).

22. van Gemert, F. et al. Impact of chronic respiratory symptoms in a rural area of sub-Saharan Africa: an in-depth qualitative study in the Masindi district of Uganda. *Prim. Care Respir. J.* **22**, 300–305 (2013).

23. Siafakas, N., Bizymi, N., Mathioudakis, A. & Corlateanu, A. EARLY versus MILD chronic obstructive pulmonary disease (COPD). *Respir. Med.* **140**, 127–131 (2018).

24. Landry, M. D., Hamdan, E., Al Mazeedi, S. & Brooks, D. The precarious balance between ‘supply’ and ‘demand’ for health care: the increasing global demand for rehabilitation service for individuals living with chronic obstructive pulmonary disease. *Int. J. Chron. Obstruct. Pulmon. Dis.* **3**, 393–396 (2008).

25. Guarnieri, M. et al. Lung function in rural Guatemalan women before and after a chimney stove intervention to reduce wood smoke exposure: results from the randomized exposure study of pollution indoors and respiratory effects and chronic respiratory effects of early childhood exposure to respirable particulate matter study. *Chest* **148**, 1184–1192 (2015).